ClinicalTrials.gg
CompletedNCT01486940Updated Jan 27, 2017

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

A Phase 3 interventional study of insulin detemir and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 75 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
598
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 1.

Enrollment
3rd of 35
598 · median 83
Started
2002
with 3 others
Phase 3
18 of 35
none open now
Registered
27th of 35
by date
Lead sponsor
25 of 35
Novo Nordisk A/S

Among the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 4 that started in 2002, is one of 18 in phase 3, and was the 27th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing Insulin Detemir in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1 diabetes on a basal/bolus regimen.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 598 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes for at least 12 months
  • Current treatment with any basal/bolus regimen or any biphasic insulin treatment for at least 6 months
  • below or equal to 35 kg/m\^2
  • below or equal to 12%

Exclusion criteria

Exclusion Criteria:

  • Proliferative retinopathy or maculopathy requiring acute treatment
  • Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the Investigator)
  • Subjects with known hypoglycaemic unawareness as judged by the Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
598 participants (actual)

Study arms

  • Experimental
    Basal/bolus regimen 1

    Drug: insulin detemir · Drug: insulin aspart

  • Active comparator
    Basal/bolus regimen 2

    Drug: insulin NPH · Drug: human soluble insulin

Interventions

07

What researchers measure

Primary outcomes

  1. HbA1c (glycosylated haemoglobin)

Secondary outcomes

  1. Intra-subject variation in home measured blood glucose (3-point blood glucose profiles)

  2. 8-point blood glucose profiles

  3. Incidence of self-recorded hypoglycaemic episodes

  4. Incidence of adverse events

08

Study locations

75 sites
  • Novo Nordisk Investigational Site
    Junin, Argentina
  • Novo Nordisk Investigational Site
    Moron, Argentina
  • Novo Nordisk Investigational Site
    Varazdin, 42 000, Croatia
  • Novo Nordisk Investigational Site
    Hradec Kralove, 50036, Czech Republic
  • Novo Nordisk Investigational Site
    Liberec, 46001, Czech Republic
  • Novo Nordisk Investigational Site
    Plzen - Lochotin, 30460, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 10, 10034, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 2, 12000, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 4, 140 00, Czech Republic
  • Novo Nordisk Investigational Site
    Praha 5, 150 18, Czech Republic
  • Novo Nordisk Investigational Site
    Hillerød, 3400, Denmark
  • Novo Nordisk Investigational Site
    Hjørring, 9800, Denmark
  • Novo Nordisk Investigational Site
    Holbæk, 4300, Denmark
  • Novo Nordisk Investigational Site
    København, 2400, Denmark
  • Novo Nordisk Investigational Site
    Køge, 4600, Denmark
  • Novo Nordisk Investigational Site
    Silkeborg, 8600, Denmark
  • Novo Nordisk Investigational Site
    Slagelse, 4200, Denmark
  • Novo Nordisk Investigational Site
    Svendborg, 5700, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Kemi, 94100, Finland
  • Novo Nordisk Investigational Site
    Kokkola, 67200, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70210, Finland
  • Novo Nordisk Investigational Site
    Oulu, FI-90220, Finland
  • Novo Nordisk Investigational Site
    Pärnu, 80010, Finland
  • Novo Nordisk Investigational Site
    Rovaniemi, 96400, Finland
  • Novo Nordisk Investigational Site
    Viljandi, 71024, Finland
  • Novo Nordisk Investigational Site
    Angers, France
  • Novo Nordisk Investigational Site
    GRENOBLE cedex, 38043, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    Lorient, 56322, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 5, 34295, France
  • Novo Nordisk Investigational Site
    Mougins, 06250, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    Paris Cedex 10, 75475, France
  • Novo Nordisk Investigational Site
    Paris, 75014, France
  • Novo Nordisk Investigational Site
    Paris, 75877, France
  • Novo Nordisk Investigational Site
    Poitiers, 86000, France
  • Novo Nordisk Investigational Site
    Athens, GR-10552, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-115 27, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Alessandria, Italy
  • Novo Nordisk Investigational Site
    Asti, 14100, Italy
  • Novo Nordisk Investigational Site
    Bari, 70100, Italy
  • Novo Nordisk Investigational Site
    Bergamo, 24127, Italy
  • Novo Nordisk Investigational Site
    Catania, 95124, Italy
  • Novo Nordisk Investigational Site
    Catania, 95126, Italy
  • Novo Nordisk Investigational Site
    Genova, 16132, Italy
  • Novo Nordisk Investigational Site
    Lucca, 55100, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Padova, 35143, Italy
  • Novo Nordisk Investigational Site
    Prato, 59100, Italy
  • Novo Nordisk Investigational Site
    Ravenna, 48121, Italy
  • Novo Nordisk Investigational Site
    Roma, 00161, Italy
  • Novo Nordisk Investigational Site
    Torino, 10126, Italy
  • Novo Nordisk Investigational Site
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • Novo Nordisk Investigational Site
    Arendal, 4841, Norway
  • Novo Nordisk Investigational Site
    Gjettum, 1346, Norway
  • Novo Nordisk Investigational Site
    Gjøvik, NO-2819, Norway
  • Novo Nordisk Investigational Site
    Kongsberg, NO-3602, Norway
  • Novo Nordisk Investigational Site
    Kongsvinger, 2212, Norway
  • Novo Nordisk Investigational Site
    Kristiansand S, 4604, Norway
  • Novo Nordisk Investigational Site
    Rådal, 5235, Norway
  • Novo Nordisk Investigational Site
    Bydgoszcz, 85-094, Poland
  • Novo Nordisk Investigational Site
    Bydgoszcz, 85-822, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-211, Poland
  • Novo Nordisk Investigational Site
    Krakow, 31-501, Poland
  • Novo Nordisk Investigational Site
    Lodz, 90-030, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-718, Poland
  • Novo Nordisk Investigational Site
    Szczecin, 71-455, Poland
  • Novo Nordisk Investigational Site
    Timisoara, 300736, Romania
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 125315, Russian Federation
  • Novo Nordisk Investigational Site
    Kosice, 043 80, Slovakia
  • Novo Nordisk Investigational Site
    Moldava nad Bodvou, 045 01, Slovakia
  • Novo Nordisk Investigational Site
    Falun, 791 82, Sweden
09

References and documents

Publications

  • Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004 Apr;47(4):622-9. doi: 10.1007/s00125-004-1365-z. PubMed 15298338 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Oct 2002 and a completion of Oct 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2011
First posted
Dec 7, 2011
Start
Mar 2002
Primary completionActual
Oct 2002
CompletionActual
Oct 2002
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01486940
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 7, 2011
Start date
Mar 2002
Primary completion
Oct 2002
Completion
Oct 2002
Last update
Jan 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Aspart

Start the discussion